ramosetron (Nasea)

Also Known As:

Nasea; 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazol; YM 060; YM-060; YM060; methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)-; ramosetron hydrochloride

Networked: 254 relevant articles (102 outcomes, 109 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - ramosetron: 254

Experts

1.	Fujii, Yoshitaka: 13 articles (12/2011 - 01/2002)
2.	Tanaka, Hiroyoshi: 8 articles (01/2005 - 01/2002)
3.	Do, Sang-Hwan: 6 articles (05/2022 - 04/2010)
4.	Akiho, Hiraku: 6 articles (01/2017 - 05/2009)
5.	Ryu, Jung-Hee: 5 articles (11/2022 - 09/2011)
6.	Kim, Jin-Tae: 5 articles (01/2020 - 04/2012)
7.	Choi, Yong Seon: 5 articles (01/2018 - 08/2008)
8.	Kwak, Young Lan: 5 articles (10/2017 - 08/2008)
9.	Fukudo, Shin: 5 articles (01/2017 - 06/2014)
10.	Ida, Motoko: 5 articles (01/2017 - 06/2014)

Related Diseases

1.	Postoperative Nausea and Vomiting (PONV) 11/01/2011 - "Compared with placebo, the efficacy of 0.3 mg ramosetron in adults and 6 µg/kg in children were consistently beneficial in preventing PONV overall (RR: 0.4; 95% CI: 03-0.6). " 01/01/2006 - "Ramosetron is effective for the long-term (up to 48 hours) prevention of PONV. " 01/01/2005 - "Ramosetron is effective for the long-term prevention of PONV. " 11/01/2011 - "Ramosetron is effective and safe in children and adults without serious adverse effects compared with placebo or other active drugs, as shown in pooled data of RCTs, in terms of the prevention of PONV." 08/01/2013 - "All double-blind randomized controlled trials that tested the efficacy of ramosetron compared with a placebo or other drugs as a control in the prophylaxis of PONV were considered to be eligible. "
2.	Vomiting 01/01/2015 - "This study shows a trend regarding the dose-response relationship for ramosetron to prevent CINV, including delayed emesis. " 12/01/2003 - "The number of emesis-free patients in the ramosetron 0.15-mg group and the placebo group were similar after both study periods. " 08/20/2005 - "The control rate of vomiting by ramosetron was 88%, 86% and 90% for the first three days. " 02/01/2004 - "Overall in 24 h, patients receiving oral ramosetron experienced no emesis slightly higher than that of the i.v. group (55% and 36% respectively, p = 0.05). " 01/01/2004 - "If vomiting occurred in the following 24 h, patients in both groups received an intravenous rescue dose of ramosetron 300 microg. "
3.	Nausea 05/12/2022 - "We found significant differences in the incidence (13% vs. 33%, P = 0.008) and severity (P = 0.011) of nausea between the ramosetron and the control groups during 24 h after discharge. " 04/01/2019 - "Moreover, its role in preventing maternal nausea together with better haemodynamic parameters further supported the advantageous role of ramosetron in our group of patients." 05/01/2016 - "The severity of nausea was significantly lower in the Ramosetron group compared with the placebo group (20.7% vs. 39.8%, NNT = 6.0) in the 24 hour period. " 01/01/2016 - "The incidence of nausea was also significantly lower in the ramosetron group at 24 h than in the other groups (P < 0.05). " 05/01/2010 - "The incidence of nausea between 2 and 24 h and the severity of nausea between 2 and 48 h were also less in the ramosetron group. "
4.	Diarrhea 06/01/2017 - "Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study." 06/01/2014 - "We performed a randomized, double-blind, placebo-controlled trial to determine whether ramosetron reduces diarrhea in these patients. " 01/01/2013 - "In a double-blind, placebo-controlled, parallel-group study of 418 patients with diarrhea-predominant IBS-D, once-daily 5 μg and 10 μg doses of ramosetron increased the monthly responder rates of IBS symptoms compared to placebo. " 05/01/2014 - "Ramosetron is under evaluation for diarrhea-predominant IBS due to its acceptable safety and tolerability, besides its efficacy. " 04/01/2013 - "Is Ramosetron Really Useful to Treat Diabetic Diarrhea With Rapid Small Bowel Transit?: Author's Reply."
5.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 07/01/2007 - "Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome." 01/01/2015 - "Irritable bowel syndrome-D Japanese subjects received 2.5 or 5 μg of ramosetron once daily for 4 weeks. " 01/01/2008 - "The monthly responder rates of 'Patient-reported global assessment of relief of irritable bowel syndrome symptoms' in the 5- and 10-microg ramosetron hydrochloride-administered groups were higher than the placebo group (26.92, 42.57, and 43.01% for placebo, 5 and 10 microg). " 11/14/2007 - "Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats." 05/01/2009 - "[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea]."

Related Drugs and Biologics

1.	Ondansetron (Zofran)
2.	Dexamethasone (Maxidex)
3.	Antiemetics
4.	Palonosetron (Aloxi)
5.	Granisetron (Kytril)
6.	Cisplatin (Platino)
7.	Serotonin (5 Hydroxytryptamine)
8.	Propofol (Diprivan)
9.	Aprepitant (Emend)
10.	Tropisetron (Navoban)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laparoscopic Cholecystectomy
3.	Patient-Controlled Analgesia (Analgesia, Patient Controlled)
4.	General Anesthesia
5.	Therapeutics